A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To explore the antiviral efficacy, tolerability and safety of saquinavir plus zidovudine plus lamivudine.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Lamivudine; Saquinavir; Zidovudine

Criteria

Inclusion Criteria

Patients must have:

• HIV antibody positive.

• CD4 count >= 150 and <= 500 cells/mm3.

Exclusion Criteria

Prior Medication:

Excluded:

• Prior antiretroviral therapy.

• Prior protease inhibitor therapy.